drugset / Trial / NCT06643078
A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD
Phase 3
Completed
487 enrolled
Haisco Pharmaceutical Group Co., Ltd.
Sichuan Haisco Pharmaceutical Group Co., Ltd · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the efficacy and safety of HL231 Solution for Inhalation vs Ultibro in Chinese patients with moderate to very severe COPD
Timeline
- Start
- 2023-12-11
- Primary completion
- 2025-05-12
- Completion
- 2025-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glycopyrronium | Unknown | 50 ug | Inhaled |
| Subject | Glycopyrronium | Unknown | 141 ug | Inhaled |
| Subject | Indacaterol | Other / unclassified | 110 ug | Inhaled |
| Subject | Indacaterol | Other / unclassified | 261 ug | Inhaled |